Phenylketonuria

Genetic MONDO:0009861 Pathograph 16 Metabolic Disease Inborn Error of Metabolism
0
Mappings
0
Definitions
1
Inheritance
11
Pathophysiology
0
Histopathology
7
Phenotypes
16
Pathograph
1
Genes
5
Treatments
3
Subtypes
4
Differentials
3
Datasets
3
Trials
5
Models
🏷

Classifications

Harrison's Chapter
hereditary disease
👪

Inheritance

1
Autosomal Recessive HP:0000007
Biallelic pathogenic PAH variants are required for disease expression.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:21555948 SUPPORT Human Clinical
"Phenylalanine hydroxylase deficiency is an autosomal recessive disorder that results in intolerance to the dietary intake of the essential amino acid phenylalanine."
Confirms autosomal recessive inheritance for PAH deficiency (PKU).
◆

Subtypes

3
Classic PKU
Severe PAH deficiency with blood Phe greater than 1200 micromol/L untreated.
Show evidence (1 reference)
PMID:21555948 SUPPORT Human Clinical
"Deficiency of this enzyme produces a spectrum of disorders including classic phenylketonuria, mild phenylketonuria, and mild hyperphenylalaninemia."
GeneReviews describes classic PKU as part of the PAH deficiency spectrum.
Mild PKU
Moderate PAH deficiency with blood Phe 600-1200 micromol/L untreated.
Show evidence (1 reference)
PMID:21555948 SUPPORT Human Clinical
"Deficiency of this enzyme produces a spectrum of disorders including classic phenylketonuria, mild phenylketonuria, and mild hyperphenylalaninemia."
Same source supports mild PKU as a recognized subtype in the PAH deficiency spectrum.
BH4-Responsive PKU
Responds to tetrahydrobiopterin supplementation.
Show evidence (1 reference)
PMID:34017006 SUPPORT Human Clinical
"Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"
Supports a BH4-responsive subgroup among PKU patients.
⚙

Pathophysiology

11
Hepatic PAH Enzyme Deficiency
Pathogenic PAH variants reduce hepatic phenylalanine hydroxylase activity.
hepatocyte link
PAH link
L-phenylalanine catabolic process link ↓ DECREASED
liver link
Show evidence (1 reference)
PMID:29025426 SUPPORT Human Clinical
"Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine."
Defines PAH deficiency as the primary molecular lesion in PKU.
Hyperphenylalaninemia
Phenylalanine accumulates in blood and tissues when PAH-dependent metabolism is impaired.
L-phenylalanine metabolic process link ↕ DYSREGULATED
Show evidence (2 references)
PMID:24385074 SUPPORT Human Clinical
"Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metabolism to be identified through population screening."
Clinical guideline abstract confirms blood phenylalanine accumulation in PKU.
PMID:21216643 SUPPORT Human Clinical
"Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
Independent clinical study confirms elevated blood phenylalanine in PKU.
Relative Tyrosine Deficiency
Decreased PAH flux lowers endogenous tyrosine generation from phenylalanine.
tyrosine metabolic process link ↓ DECREASED
Show evidence (2 references)
PMID:29025426 SUPPORT Human Clinical
"Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine."
Impaired conversion from phenylalanine to tyrosine implies substrate deficiency downstream.
PMID:21216643 SUPPORT Human Clinical
"Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
Human PKU cohort data directly reports reduced tyrosine associated with hyperphenylalaninemia.
Competitive Large Neutral Amino Acid Transport at the Blood-Brain Barrier
Large neutral amino acids, including phenylalanine, share competitive brain-entry transport.
neutral amino acid transport link ↕ DYSREGULATED
blood brain barrier link
Show evidence (1 reference)
PMID:987768 SUPPORT Model Organism
"The LNAA group of amino acids--phenylalanine, tyrosine, tryptophan, leucine, isoleucine, and valine--compete with each other for entry into brain by a common transport mechanism."
Provides mechanistic support for competitive BBB amino acid transport.
Reduced Serotonin Biosynthesis
High phenylalanine states inhibit serotonin production pathways.
serotonin biosynthetic process link ↓ DECREASED
Show evidence (1 reference)
PMID:6119011 SUPPORT Human Clinical
"In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."
Human PKU data support reduced serotonin synthesis under high phenylalanine conditions.
Reduced Dopamine Biosynthesis
High phenylalanine states inhibit dopamine production pathways.
dopamine biosynthetic process link ↓ DECREASED
Show evidence (1 reference)
PMID:6119011 SUPPORT Human Clinical
"In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."
Human PKU data support reduced dopamine synthesis under high phenylalanine conditions.
Brain Phenylalanine Toxicity
Elevated phenylalanine in the CNS drives diffuse brain dysfunction.
nervous system development link ⚠ ABNORMAL
brain link
Show evidence (1 reference)
PMID:34017006 SUPPORT Human Clinical
"Phenylketonuria (PKU; also known as phenylalanine hydroxylase (PAH) deficiency) is an autosomal recessive disorder of phenylalanine metabolism, in which especially high phenylalanine concentrations cause brain dysfunction."
Confirms high phenylalanine concentrations as a direct driver of brain dysfunction.
White Matter and Subcortical Structural Injury
Treated adults still exhibit white-matter damage and subcortical volume loss associated with phenylalanine burden.
oligodendrocyte link
myelination link ⚠ ABNORMAL
white matter link
Show evidence (2 references)
PMID:37265600 SUPPORT Human Clinical
"In conclusion, our findings demonstrate that white matter alterations in early-treated phenylketonuria persist into adulthood, are most prominent in the posterior white matter and are likely to be driven by axonal damage."
Supports persistent white matter injury in adults with early-treated PKU.
PMID:38907189 SUPPORT Human Clinical
"Moreover, these patients showed reduced global white matter volume as well as reductions in the volume of several subcortical grey matter structures, which might be related to the existence of underlying neurodevelopmental alterations."
Independently confirms white matter and subcortical structural abnormalities.
Neurocognitive Dysfunction
PKU causes global and executive cognitive impairment, especially when metabolic control is poor or untreated.
neuron link
Show evidence (1 reference)
PMID:38907189 SUPPORT Human Clinical
"Adult patients with early-treated PKU showed significantly lower global intelligence than HC."
Demonstrates measurable cognitive impairment in early-treated adult PKU cohorts.
Impaired Melanin Biosynthesis
Reduced tyrosine availability limits melanin synthesis in untreated or poorly controlled disease.
melanin biosynthetic process link ↓ DECREASED
Show evidence (1 reference)
PMID:30570999 SUPPORT Human Clinical
"These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
Fair skin in PKU is consistent with reduced pigmentation downstream of tyrosine deficit.
Phenylketone Accumulation
Alternative phenylalanine metabolism increases phenylketones such as phenylpyruvate.
Show evidence (1 reference)
PMID:21565303 SUPPORT Human Clinical
"The urinary metabolic marker compounds, namely phenylpyruvic acid (PPA), 2-hydroxyphenylacetic acid (oOPAA), 4-hydroxyphenylacetic acid (pOPAA), phenyllactic acid (PLA) and phenylacetic acid (PAA) of phenylketonuric individuals were detected"
Confirms phenylketone metabolite accumulation in PKU urine profiles.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Phenylketonuria Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Head and Neck 1
Microcephaly FREQUENT Microcephaly (HP:0000252)
Result of impaired brain development
Show evidence (2 references)
PMID:17092471 SUPPORT Human Clinical
"In addition to well-known findings such as mental retardation, autistic features, microcephaly, and tremor, motor retardation was common and responded promptly to dietary treatment."
Pediatric PKU case series documents microcephaly among established neurologic manifestations.
PMID:35854334 SUPPORT Human Clinical
"Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."
Review abstract independently supports acquired microcephaly in untreated PKU.
Immune 1
Eczema FREQUENT Eczematoid dermatitis (HP:0000964)
Show evidence (1 reference)
PMID:30570999 SUPPORT Human Clinical
"These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
Clinical overview explicitly lists eczema among PKU manifestations.
Integument 1
Hypopigmentation VERY_FREQUENT Hypopigmentation of the skin (HP:0001010)
Fair skin, light hair, blue eyes due to melanin deficiency
Show evidence (2 references)
PMID:35854334 SUPPORT Human Clinical
"Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."
Supports generalized skin, hair, and eye hypopigmentation as a PKU phenotype.
PMID:30570999 SUPPORT Human Clinical
"These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
Fair skin in PKU is consistent with clinical hypopigmentation.
Musculoskeletal 1
Hypertonia OCCASIONAL Hypertonia (HP:0001276)
Reported in untreated/poorly controlled disease; less frequent than hypotonia in pediatric series.
Show evidence (2 references)
PMID:17092471 SUPPORT Human Clinical
"Hypotonia and diminished reflexes were more frequent findings than hypertonia."
Confirms hypertonia occurs in PKU while indicating lower relative frequency.
PMID:2516176 SUPPORT Human Clinical
"Dietary therapy reduced serum phenylalanine levels, improved symptoms of hypertonicity, and cerebrospinal fluid neurotransmitter metabolites became normal."
Adult PKU report supports clinically significant hypertonicity as a neurologic manifestation.
Nervous System 2
Intellectual Disability VERY_FREQUENT Intellectual disability (HP:0001249)
Develops if untreated, preventable with early dietary treatment
Show evidence (2 references)
PMID:34017006 SUPPORT Human Clinical
"If untreated, this brain dysfunction results in severe intellectual disability, epilepsy and behavioural problems."
The Nature Reviews Primer confirms severe intellectual disability as a key untreated phenotype.
PMID:38907189 PARTIAL Human Clinical
"Adult patients with PKU showed significantly lower performance than HC in Full Scale IQ"
Even early-treated adults show lower IQ compared to healthy controls.
Seizures FREQUENT Seizure (HP:0001250)
Common in untreated patients
Show evidence (1 reference)
PMID:29025426 SUPPORT Human Clinical
"If left untreated, PKU results in increased phenylalanine concentrations in blood and brain, which cause severe intellectual disability, epilepsy and behavioural problems."
European guidelines confirm epilepsy as a major untreated manifestation.
Constitutional 1
Musty Odor FREQUENT Musty odor (HP:0410021)
Due to phenylacetic acid in sweat and urine
Show evidence (1 reference)
PMID:30570999 SUPPORT Human Clinical
"These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
Clinical overview directly supports musty body odor as a characteristic PKU sign.
🧬

Genetic Associations

1
PAH (Causative)
Show evidence (2 references)
PMID:35854334 SUPPORT Human Clinical
"PKU, an autosomal recessive disease, is an inborn error of phenylalanine (Phe) metabolism caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene."
Directly supports PAH as the causative gene in classical PKU.
PMID:35952926 SUPPORT Human Clinical
"Thirty-three PAH variants and five PTS variants were detected in HPA patients; 80.6 % PAH variants and 100 % PTS variants were classified as pathogenic or likely pathogenic."
Provides cohort-level evidence for multiple pathogenic PAH variants in HPA/PKU.
💊

Treatments

5
Phenylalanine-Restricted Diet
Action: dietary intervention MAXO:0000088
Diet: restrict mammalian meat food product ↗ restrict milk ↗ restrict nut ↗
Lifelong dietary restriction of phenylalanine intake, mainstay of treatment.
Show evidence (2 references)
PMID:34017006 SUPPORT Human Clinical
"Dietary restriction of phenylalanine has been the mainstay of treatment for over 60 years and has been highly successful, although outcomes are still suboptimal and patients can find the treatment difficult to adhere to."
Confirms diet as the primary and long-standing treatment approach.
PMID:21555948 SUPPORT Human Clinical
"The mainstay of treatment for hyperphenylalaninemia involves a low-protein diet and use of a phenylalanine-free medical formula."
Independent clinical review confirms low-protein dietary treatment as standard of care.
Medical Formula
Action: dietary intervention MAXO:0000088
Phenylalanine-free amino acid supplements to provide protein needs.
Show evidence (2 references)
PMID:21555948 SUPPORT Human Clinical
"The mainstay of treatment for hyperphenylalaninemia involves a low-protein diet and use of a phenylalanine-free medical formula."
Directly supports phenylalanine-free medical formula as standard PKU therapy.
PMID:35854334 SUPPORT Human Clinical
"Dietary treatment, including natural protein restriction and Phe-free supplements, must be used to maintain blood Phe concentrations of 120-360 μmol/L throughout the life span."
Independent review confirms ongoing use of Phe-free supplementation in PKU management.
Sapropterin (Kuvan)
Action: pharmacotherapy MAXO:0000058
Agent: sapropterin ↗
BH4 cofactor replacement for responsive patients, allows dietary liberalization.
Show evidence (2 references)
PMID:34017006 SUPPORT Human Clinical
"Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"
Confirms sapropterin (BH4) effectiveness in a subset of patients with milder disease.
PMID:17693179 SUPPORT Human Clinical
"In some patients with phenylketonuria who are responsive to BH4, sapropterin treatment to reduce blood phenylalanine could be used as an adjunct to a restrictive low-phenylalanine diet, and might even replace the diet in some instances."
Phase III trial evidence supports sapropterin efficacy in BH4-responsive PKU.
Pegvaliase (Palynziq)
Action: pharmacotherapy MAXO:0000058
Agent: pegvaliase ↗
Enzyme substitution therapy using PEGylated phenylalanine ammonia lyase.
Show evidence (2 references)
PMID:34017006 PARTIAL Human Clinical
"pegylated phenylalanine ammonia lyase, which requires daily subcutaneous injections and causes adverse immune responses"
Confirms pegvaliase as an available treatment, noting its route and immunogenicity concerns.
PMID:29628378 SUPPORT Human Clinical
"Results from this study confirmed the efficacy of pegvaliase in maintaining reduced blood Phe concentrations with a manageable safety profile for most participants."
Pivotal Phase 3 trial independently supports pegvaliase efficacy and tolerability profile.
Large Neutral Amino Acids
Action: dietary intervention MAXO:0000088
Compete with phenylalanine for brain transport, adjunctive therapy.
Show evidence (2 references)
PMID:987768 SUPPORT Model Organism
"Increasing the serum concentrations of amino acids competitive with phenylalanine for transport across the blood brain barrier might form an alternative approach to effective dietary treatment of PKU."
Supports LNAA supplementation rationale as an adjunctive PKU dietary strategy.
PMID:35854334 SUPPORT Human Clinical
"Additional treatments include the casein glycomacropeptide (GMP), which contains very limited aromatic amino acids and may improve immunological function, and large neutral amino acid (LNAA) supplementation to prevent plasma Phe transport into the brain."
Human PKU review independently supports LNAA supplementation as an adjunctive treatment strategy.
🌍

Environmental Factors

5
Dietary Phenylalanine
Primary determinant of metabolic control
Show evidence (2 references)
PMID:24385074 SUPPORT Human Clinical
"Treatment has predominantly been dietary manipulation, and use of low protein and phenylalanine medical foods is likely to remain a major component of therapy for the immediate future."
Supports that phenylalanine intake control through diet is central to metabolic management.
PMID:35854334 SUPPORT Human Clinical
"Dietary treatment, including natural protein restriction and Phe-free supplements, must be used to maintain blood Phe concentrations of 120-360 μmol/L throughout the life span."
Independent review supports dietary phenylalanine restriction as a central environmental determinant of metabolic control.
Mammalian Meat Intake
mammalian meat food product link
Representative high-protein phenylalanine-rich food source requiring restriction
Dairy Intake
milk link
Milk and related dairy foods contribute to dietary phenylalanine burden
Nut Intake
nut link
Nuts are concentrated protein sources that contribute to dietary phenylalanine burden
Aspartame
Contains phenylalanine, must be avoided
Show evidence (2 references)
PMID:33672234 SUPPORT Human Clinical
"Aspartame is a phenylalanine containing sweetener, added to foods and drinks, which is avoided in phenylketonuria (PKU)."
Directly supports aspartame avoidance as a relevant environmental exposure issue in PKU.
PMID:3291200 SUPPORT Human Clinical
"Persons suffering from phenylketonuria (PKU-homozygotes) on a phenylalanine-restricted diet should avoid consumption of aspartame."
Independent review supports specific aspartame avoidance guidance in PKU.
🔬

Biochemical Markers

4
Blood Phenylalanine (Elevated)
Context: Greater than 120 micromol/L, often greater than 1200 micromol/L in classic PKU
Show evidence (2 references)
PMID:24385074 SUPPORT Human Clinical
"Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metabolism to be identified through population screening."
Supports elevated blood phenylalanine as the defining biochemical abnormality.
PMID:21216643 SUPPORT Human Clinical
"Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
Independent human cohort evidence confirms elevated blood phenylalanine in PKU.
Blood Tyrosine (Decreased)
Context: Low due to blocked conversion from phenylalanine
Show evidence (2 references)
PMID:30570999 SUPPORT Human Clinical
"Elevated blood Phe levels and decreased Tyr levels characterize PKU."
Directly supports low tyrosine as a characteristic biochemical feature.
PMID:21216643 SUPPORT Human Clinical
"Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
Independent cohort data explicitly reports reduced tyrosine in PKU.
Phenylalanine to Tyrosine Ratio (Elevated)
Context: Diagnostic marker
Show evidence (2 references)
PMID:35952926 SUPPORT Human Clinical
"All patients had elevated Phe and Phe/Tyr levels."
Supports elevation of the phenylalanine:tyrosine index in diagnosed HPA/PKU cohorts.
PMID:21216643 SUPPORT Human Clinical
"Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
Independent clinical data supports elevated Phe/Tyr ratio as a core PKU biochemical marker.
Phenylpyruvic Acid (Elevated)
Context: Alternative metabolite in urine
Show evidence (1 reference)
PMID:21565303 SUPPORT Human Clinical
"The urinary metabolic marker compounds, namely phenylpyruvic acid (PPA), 2-hydroxyphenylacetic acid (oOPAA), 4-hydroxyphenylacetic acid (pOPAA), phenyllactic acid (PLA) and phenylacetic acid (PAA) of phenylketonuric individuals were detected"
Supports urinary phenylpyruvic acid elevation as part of the PKU metabolite profile.
🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Phenylketonuria:

Hyperphenylalaninemia due to tetrahydrobiopterin deficiency Not Yet Curated MONDO:0016543
Overlapping Features BH4 cofactor defects can present as newborn-screen positive hyperphenylalaninemia and mimic PAH deficiency.
Distinguishing Features
  • Differential testing is required because BH4 deficiency can present with the same initial hyperphenylalaninemia signal as PKU.
  • Separation from PAH deficiency relies on pterin studies and DHPR enzyme activity testing.
  • Patients may develop neurologic abnormalities despite acceptable blood phenylalanine control.
Show evidence (2 references)
PMID:35952926 SUPPORT Human Clinical
"Newborn screening is an effective method for early detection of HPA, but differential diagnosis of BH4D is necessary."
Explicitly states that BH4 deficiency must be differentiated from PAH-related hyperphenylalaninemia.
PMID:8404969 SUPPORT Human Clinical
"We describe a new fully reliable method for the differential diagnosis of tetrahydrobiopterin-dependent hyperphenylalaninaemia (HPA)."
Supports dedicated differential workup for BH4-dependent forms.
Dihydropteridine Reductase Deficiency Not Yet Curated MONDO:0009862
Overlapping Features A BH4 regeneration disorder causing hyperphenylalaninemia with monoamine neurotransmitter deficiency.
Distinguishing Features
  • DHPR activity testing on dried blood spots is recommended during differential diagnosis.
  • Distinguishing this disorder from PAH deficiency changes treatment strategy beyond phenylalanine restriction alone.
Show evidence (2 references)
PMID:3930839 SUPPORT Human Clinical
"Measurement of DHPR activity in blood spots on Guthrie cards is recommended."
Confirms DHPR enzyme testing as a key discriminator in hyperphenylalaninemia workup.
PMID:8404969 SUPPORT Human Clinical
"It should be performed together with the measurement of dihydropteridine reductase (DHPR) activity in blood."
Reinforces that differential diagnosis requires specific DHPR testing.
BH4-deficient hyperphenylalaninemia A Not Yet Curated MONDO:0009863
Overlapping Features PTS-related BH4 synthesis deficiency that phenotypically overlaps with PKU on newborn screening.
Distinguishing Features
  • Caused by BH4 pathway defects (including PTS variants) rather than PAH enzyme deficiency.
  • Requires BH4-focused biochemical and/or genetic testing to identify correctly.
Show evidence (2 references)
PMID:35952926 SUPPORT Human Clinical
"Of the 296 newborns who tested HPA positive, 56 were diagnosed with HPA, including 47 with phenylalanine hydroxylase deficiency and nine with tetrahydrobiopterin deficiency (BH4D)."
Demonstrates a real newborn-screen cohort where BH4-deficient cases coexist with PAH deficiency and require distinction.
PMID:35952926 SUPPORT Human Clinical
"Thirty-three PAH variants and five PTS variants were detected in HPA patients;"
Supports genetic differentiation between PAH-related PKU and PTS-related BH4 deficiency.
Mild Hyperphenylalaninemia Not Yet Curated MONDO:0019335
Overlapping Features A milder PAH-spectrum condition with lower untreated phenylalanine burden and lower neurologic risk than classic PKU.
Distinguishing Features
  • Lower baseline phenylalanine elevations and substantially reduced risk of severe cognitive impairment compared with classic PKU.
  • Phenylalanine thresholds for lifelong intensive treatment differ from classic PKU-range disease.
Show evidence (2 references)
PMID:21555948 SUPPORT Human Clinical
"Mild phenylketonuria and mild hyperphenylalaninemia are associated with lower risk of impaired cognitive development in the absence of treatment."
Supports lower neurodevelopmental risk profile relative to classic untreated PKU.
PMID:39630157 SUPPORT Human Clinical
"treatment for PAH deficiency should be lifelong for individuals with untreated phenylalanine (Phe) levels >360 μmol/L"
Guideline threshold helps distinguish lower-range hyperphenylalaninemia from classic PKU requiring strict lifelong treatment targets.
📊

Related Datasets

3
Whole transcriptome comparison between two groups of PKU patients: Non-carriers vs. Carriers of rs113883650 geo:GSE294755
Transcriptomic profiling dataset comparing PKU carrier/non-carrier groups under differing phenylalanine exposure conditions.
Homo sapiens MICROARRAY n=19
patient-derived cells
Conditions: PKU non-carrier group PKU carrier group (rs113883650) high phenylalanine condition low phenylalanine condition
Findings
High-phenylalanine conditions in this cohort were associated with reduced expression of proteasome pathway genes.
Show evidence (1 reference)
geo:GSE294755 SUPPORT In Vitro
"We demonstrated a decrease of expression of proteasome pathway (KEGG) incells treated with high Phe concentrations."
GEO summary reports pathway-level transcriptomic changes under high phenylalanine exposure.
PMID:41387948
Show evidence (1 reference)
geo:GSE294755 SUPPORT In Vitro
"We demonstrated a decrease of expression of proteasome pathway (KEGG) incells treated with high Phe concentrations."
Dataset-level summary supports relevance to PKU high-phenylalanine cellular response.
Does early treatment of PKU patients with sapropterin dihydrochloride affect brain development? geo:GSE112108
RNA-seq from organotypic rat brain cultures exposed to sepiapterin/BH4 to model developmental effects relevant to early PKU treatment contexts.
Rattus norvegicus BULK RNA SEQ n=23
organotypic brain cell culture
Conditions: sepiapterin-treated untreated control early developmental stage later developmental stage
Findings
Early-stage sepiapterin exposure showed transcriptomic and cellular evidence of disturbed neural development, with increased apoptosis and altered glial/axonal markers.
Show evidence (2 references)
geo:GSE112108 SUPPORT In Vitro
"RNAseq analyses revealed a number of significantly affected genes."
Dataset summary confirms measurable transcriptional perturbations in treated developing brain cultures.
geo:GSE112108 SUPPORT In Vitro
"Immunofluorescence for activated caspase-3 revealed an increased apoptosis rate."
Summary links treatment exposure to increased apoptosis in the early developmental stage.
Show evidence (1 reference)
geo:GSE112108 SUPPORT In Vitro
"RNAseq analyses revealed a number of significantly affected genes."
Supports utility of this dataset for transcriptomic analysis of early PKU-treatment-relevant brain effects.
Mildly compromised tetrahydrobiopterin biosynthesis mouse mutants exhibit abnormal body fat distribution and abdominal obesity geo:GSE55148
Mouse expression profiling study of reduced BH4 biosynthesis (Pts mutant models), relevant to BH4-deficient hyperphenylalaninemia mechanisms.
Mus musculus MICROARRAY n=16
brain tissue liver tissue
Conditions: Pts mutant mice wild-type controls
Findings
BH4-biosynthesis impairment in this model produced metabolic phenotypes relevant to BH4-associated hyperphenylalaninemia.
Show evidence (1 reference)
geo:GSE55148 SUPPORT Model Organism
"BH4 deficiency due to an autosomal recessive defect in its biosynthetic enzyme 6-pyruvoyltetrahydropterin synthase (PTPS, encoded by the PTS gene) leads to a variant form of hyperphenylalaninemia concomitant with severe deficiency of brain monoamine neurotransmitters."
Summary supports translational relevance of BH4-pathway models to differential hyperphenylalaninemia biology.
Show evidence (1 reference)
geo:GSE55148 SUPPORT Model Organism
"BH4 deficiency due to an autosomal recessive defect in its biosynthetic enzyme 6-pyruvoyltetrahydropterin synthase (PTPS, encoded by the PTS gene) leads to a variant form of hyperphenylalaninemia concomitant with severe deficiency of brain monoamine neurotransmitters."
Dataset-level summary supports relevance to BH4-associated hyperphenylalaninemia mechanisms.
🔬

Clinical Trials

3
NCT00838435 PHASE_III COMPLETED
Phase 3b open-label Kuvan study in young children with PKU evaluating safety, neurocognitive outcomes, blood phenylalanine maintenance, and growth.
Target Phenotypes: Intellectual Disability ↗
Show evidence (1 reference)
clinicaltrials:NCT00838435 SUPPORT Human Clinical
"This multicenter, open label study is designed to evaluate the safety of Kuvan® and its effect on neurocognitive function, blood Phe concentration, and growth in children with PKU who are 0-6 years old."
Trial synopsis confirms explicit clinical endpoints relevant to PKU neurocognitive disease burden.
NCT01212744 PHASE_II COMPLETED
Phase 2 open-label trial of daily subcutaneous rAvPAL-PEG evaluating safety, tolerability, and efficacy for blood phenylalanine reduction in PKU.
Target Phenotypes: Intellectual Disability ↗ Seizures ↗
Show evidence (1 reference)
clinicaltrials:NCT01212744 SUPPORT Human Clinical
"The purpose of this study is to evaluate the effect of daily administration of rAvPAL-PEG on the reduction of blood Phe concentrations in subjects with PKU."
Confirms interventional targeting of the core biochemical driver in PKU.
NCT04534842 PHASE_II COMPLETED
Open-label Phase 2 SynPheny-1 trial assessing efficacy and safety of SYNB1618/SYNB1934 oral biotherapeutic regimens in PKU.
Target Phenotypes: Intellectual Disability ↗
Show evidence (1 reference)
clinicaltrials:NCT04534842 SUPPORT Human Clinical
"This Phase 2 study in patients with phenylketonuria (PKU) will be an open-label, dual-arm study of either a SYNB1618 or SYNB1934 dose-ramp regimen."
Confirms active interventional evaluation of novel PKU therapeutics in a defined patient cohort.
🧮

Computational Models

5
Multi-compartment PKU FBA Model FLUX_BALANCE_ANALYSIS
Three-compartment FBA model with explicit blood-brain barrier transport for aromatic amino acids
PMID:36880400 ↗ Base model: Recon-derived
Explains brain-specific pathology and why Phe restriction outperforms Tyr supplementation
Show evidence (1 reference)
PMID:36880400 SUPPORT Computational
"We built a three-compartment model, made the common transport across the BBB explicit, and included dopamine and serotonin synthesis as parts of the brain function to be delivered by FBA."
Directly supports model architecture and PKU-relevant mechanistic scope.
Recon3D with PAH knockout SBML COBRApy GENOME_SCALE_METABOLIC
Human genome-scale metabolic model simulating phenylalanine hydroxylase deficiency
Repository ↗ PMID:29457794 ↗ Base model: Recon3D
Show evidence (1 reference)
PMID:29457794 SUPPORT Computational
"Recon3D represents the most comprehensive human metabolic network model to date, accounting for 3,288 open reading frames (representing 17% of functionally annotated human genes), 13,543 metabolic reactions involving 4,140 unique metabolites, and 12,890 protein structures."
Supports use of Recon3D as a genome-scale computational base model for metabolic disease simulation.
Harvey Whole-Body PKU Model GENOME_SCALE_METABOLIC
Sex-specific whole-body model for organ-resolved IEM biomarker prediction.
Repository ↗ PMID:32463598 ↗ Base model: Harvey 1.0
Whole-body WBM framework supports organ-resolved biomarker prediction in inherited metabolic disease.
Show evidence (2 references)
PMID:32463598 SUPPORT Computational
"We developed a new metabolic network reconstruction approach that used organ-specific information from literature and omics data to generate two sex-specific whole-body metabolic (WBM) reconstructions."
Supports whole-body sex-specific metabolic reconstruction framework underlying Harvey/Harvetta-style models.
PMID:32463598 SUPPORT Computational
"We also illustrate that the WBM models can predict known biomarkers of inherited metabolic diseases in different biofluids."
Supports biomarker prediction capability relevant to PKU and related IEM applications.
Full-Length PAH Tetramer Crystal Structure STRUCTURAL_PREDICTION
Crystal structure of full-length human phenylalanine hydroxylase (hPAH) tetramer at 3.06 angstrom resolution in the resting-state conformation, combined with SEC-SAXS analysis of both resting and Phe-activated states. Reveals that allosteric Phe binding favors an activated tetramer conformation biophysically distinct in solution, with the Phe-binding regulatory module positioned 8-10 angstrom farther from the tetramer center than previously modeled.
PMID:31076506 ↗
Findings
First crystal structure of full-length PAH tetramer reveals resting-state architecture
Allosteric Phe binding induces a distinct activated conformation detectable by SAXS
Show evidence (2 references)
PMID:31076506 SUPPORT Computational
"a tractable C29S variant of hPAH (C29S) yielded a 3.06 Å resolution crystal structure of the tetrameric resting-state conformation."
First crystal structure of full-length PAH provides structural basis for understanding PKU-causing mutations.
PMID:31076506 SUPPORT Computational
"The structural insights into allosteric activation of hPAH reported here may help inform ongoing efforts to treat phenylketonuria with novel therapeutic approaches."
Structural insights directly relevant to PKU therapeutic development.
PAH Regulatory Domain Phe-Binding Crystal Structure STRUCTURAL_PREDICTION
Crystal structure of the human PAH N-terminal regulatory domain (PAH-RD) bound with Phe at 1.8 angstrom resolution, revealing a homodimer of ACT folds with Phe bound at the dimer interface. Demonstrates that Phe binding mediates dimerization of regulatory modules, providing structural evidence for the allosteric activation mechanism and explaining how disease-associated mutations that impair Phe binding disrupt the monomer:dimer equilibrium.
PMID:27049649 ↗
Findings
Phe binds at the dimer interface of PAH regulatory domain ACT folds
Disease-associated PAH mutations impair Phe binding and disrupt regulatory domain dimerization
Show evidence (1 reference)
PMID:27049649 SUPPORT Computational
"a disease-associated PAH mutant impaired in Phe binding disrupts the monomer:dimer equilibrium of PAH-RD."
Crystal structure explains how PKU-causing mutations disrupt allosteric regulation of PAH activity.
{ }

Source YAML

click to show 
name: Phenylketonuria
creation_date: '2025-12-19T14:27:56Z'
updated_date: '2026-04-06T00:30:00Z'
category: Genetic
parents:
- Metabolic Disease
- Inborn Error of Metabolism
disease_term:
  preferred_term: phenylketonuria
  term:
    id: MONDO:0009861
    label: phenylketonuria
has_subtypes:
- name: Classic PKU
  description: Severe PAH deficiency with blood Phe greater than 1200 micromol/L untreated.
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Deficiency of this enzyme produces a spectrum of disorders including classic phenylketonuria, mild phenylketonuria, and mild hyperphenylalaninemia."
    explanation: GeneReviews describes classic PKU as part of the PAH deficiency spectrum.
- name: Mild PKU
  description: Moderate PAH deficiency with blood Phe 600-1200 micromol/L untreated.
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Deficiency of this enzyme produces a spectrum of disorders including classic phenylketonuria, mild phenylketonuria, and mild hyperphenylalaninemia."
    explanation: Same source supports mild PKU as a recognized subtype in the PAH deficiency spectrum.
- name: BH4-Responsive PKU
  description: Responds to tetrahydrobiopterin supplementation.
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"
    explanation: Supports a BH4-responsive subgroup among PKU patients.
inheritance:
- name: Autosomal Recessive
  description: Biallelic pathogenic PAH variants are required for disease expression.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylalanine hydroxylase deficiency is an autosomal recessive disorder that results in intolerance to the dietary intake of the essential amino acid phenylalanine."
    explanation: Confirms autosomal recessive inheritance for PAH deficiency (PKU).
prevalence:
- population: Global neonatal screening cohorts
  percentage: 6.002 per 100,000 neonates
  notes: >-
    A meta-analysis focused on classic PKU found a pooled global prevalence of
    6.002 per 100,000 neonates, with marked regional variation. Broader PAH
    deficiency estimates are similar in magnitude at about 0.64 per 10,000
    births globally.
  evidence:
  - reference: PMID:32024337
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The overall worldwide prevalence of the disease is 6.002 per 100,000 neonates (95% confidence interval, 5.07-6.93)."
    explanation: This systematic review and meta-analysis provides a pooled global neonatal prevalence estimate for classic PKU.
  - reference: PMID:34082800
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was 0.64 (95% confidence interval 0.53-0.75) per 10,000 births"
    explanation: This meta-analysis of newborn screening studies supports a similar global birth prevalence estimate for the broader PAH deficiency spectrum that includes PKU.
pathophysiology:
- name: Hepatic PAH Enzyme Deficiency
  description: Pathogenic PAH variants reduce hepatic phenylalanine hydroxylase activity.
  genes:
  - preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
    modifier: DECREASED
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  biological_processes:
  - preferred_term: L-phenylalanine catabolic process
    term:
      id: GO:0006559
      label: L-phenylalanine catabolic process
    modifier: DECREASED
  evidence:
  - reference: PMID:29025426
    reference_title: "The complete European guidelines on phenylketonuria: diagnosis and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine."
    explanation: Defines PAH deficiency as the primary molecular lesion in PKU.
  downstream:
  - target: Hyperphenylalaninemia
    description: Reduced PAH activity impairs phenylalanine clearance from blood.
    evidence:
    - reference: PMID:24385074
      reference_title: "Phenylalanine hydroxylase deficiency: diagnosis and management guideline."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metabolism to be identified through population screening."
      explanation: Links PAH deficiency directly to elevated blood phenylalanine.
  - target: Relative Tyrosine Deficiency
    description: Blocked conversion of phenylalanine to tyrosine reduces tyrosine availability.
    evidence:
    - reference: PMID:29025426
      reference_title: "The complete European guidelines on phenylketonuria: diagnosis and treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine."
      explanation: The blocked PAH reaction mechanistically implies reduced tyrosine production.
- name: Hyperphenylalaninemia
  description: Phenylalanine accumulates in blood and tissues when PAH-dependent metabolism is impaired.
  chemical_entities:
  - preferred_term: L-phenylalanine
    term:
      id: CHEBI:58095
      label: L-phenylalanine zwitterion
    modifier: INCREASED
  biological_processes:
  - preferred_term: L-phenylalanine metabolic process
    term:
      id: GO:0006558
      label: L-phenylalanine metabolic process
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:24385074
    reference_title: "Phenylalanine hydroxylase deficiency: diagnosis and management guideline."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metabolism to be identified through population screening."
    explanation: Clinical guideline abstract confirms blood phenylalanine accumulation in PKU.
  - reference: PMID:21216643
    reference_title: "The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
    explanation: Independent clinical study confirms elevated blood phenylalanine in PKU.
  downstream:
  - target: Competitive Large Neutral Amino Acid Transport at the Blood-Brain Barrier
    description: Excess phenylalanine competitively perturbs transport of other neutral amino acids into brain.
    evidence:
    - reference: PMID:987768
      reference_title: "Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The LNAA group of amino acids--phenylalanine, tyrosine, tryptophan, leucine, isoleucine, and valine--compete with each other for entry into brain by a common transport mechanism."
      explanation: Demonstrates the shared competitive transport mechanism driving brain amino-acid imbalance.
  - target: Brain Phenylalanine Toxicity
    description: Persistent systemic hyperphenylalaninemia increases brain phenylalanine burden and toxicity.
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylketonuria (PKU; also known as phenylalanine hydroxylase (PAH) deficiency) is an autosomal recessive disorder of phenylalanine metabolism, in which especially high phenylalanine concentrations cause brain dysfunction."
      explanation: Directly links high phenylalanine levels to brain dysfunction.
  - target: Phenylketone Accumulation
    description: Excess phenylalanine is diverted to alternative metabolites, including phenylketones.
    evidence:
    - reference: PMID:21565303
      reference_title: "Study on urinary metabolic profile of phenylketonuria by micellar electrokinetic capillary chromatography with dual electrochemical detection--potential clinical application in fast diagnosis of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The urinary metabolic marker compounds, namely phenylpyruvic acid (PPA), 2-hydroxyphenylacetic acid (oOPAA), 4-hydroxyphenylacetic acid (pOPAA), phenyllactic acid (PLA) and phenylacetic acid (PAA) of phenylketonuric individuals were detected"
      explanation: Supports accumulation of phenylalanine-derived phenylketone metabolites in PKU.
- name: Relative Tyrosine Deficiency
  description: Decreased PAH flux lowers endogenous tyrosine generation from phenylalanine.
  chemical_entities:
  - preferred_term: L-tyrosine
    term:
      id: CHEBI:58315
      label: L-tyrosine zwitterion
    modifier: DECREASED
  biological_processes:
  - preferred_term: tyrosine metabolic process
    term:
      id: GO:0006570
      label: tyrosine metabolic process
    modifier: DECREASED
  evidence:
  - reference: PMID:29025426
    reference_title: "The complete European guidelines on phenylketonuria: diagnosis and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine."
    explanation: Impaired conversion from phenylalanine to tyrosine implies substrate deficiency downstream.
  - reference: PMID:21216643
    reference_title: "The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
    explanation: Human PKU cohort data directly reports reduced tyrosine associated with hyperphenylalaninemia.
  downstream:
  - target: Impaired Melanin Biosynthesis
    description: Reduced tyrosine supply limits melanin production.
    evidence:
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."
      explanation: Clinical hypopigmentation supports impaired melanin synthesis downstream of tyrosine deficiency.
  - target: Reduced Dopamine Biosynthesis
    description: Lower tyrosine availability reduces substrate supply for catecholamine synthesis.
    evidence:
    - reference: PMID:6119011
      reference_title: "Serotonin and dopamine synthesis in phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."
      explanation: Supports reduced dopamine biosynthesis in the PKU biochemical context.
- name: Competitive Large Neutral Amino Acid Transport at the Blood-Brain Barrier
  description: Large neutral amino acids, including phenylalanine, share competitive brain-entry transport.
  locations:
  - preferred_term: blood brain barrier
    term:
      id: UBERON:0000120
      label: blood brain barrier
  biological_processes:
  - preferred_term: neutral amino acid transport
    term:
      id: GO:0015804
      label: neutral amino acid transport
    modifier: DYSREGULATED
  chemical_entities:
  - preferred_term: L-phenylalanine
    term:
      id: CHEBI:58095
      label: L-phenylalanine zwitterion
    modifier: INCREASED
  - preferred_term: L-tyrosine
    term:
      id: CHEBI:58315
      label: L-tyrosine zwitterion
    modifier: DECREASED
  - preferred_term: L-tryptophan
    term:
      id: CHEBI:57912
      label: L-tryptophan zwitterion
    modifier: DECREASED
  evidence:
  - reference: PMID:987768
    reference_title: "Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The LNAA group of amino acids--phenylalanine, tyrosine, tryptophan, leucine, isoleucine, and valine--compete with each other for entry into brain by a common transport mechanism."
    explanation: Provides mechanistic support for competitive BBB amino acid transport.
  downstream:
  - target: Reduced Serotonin Biosynthesis
    description: Lower brain tryptophan availability contributes to impaired serotonin synthesis.
    evidence:
    - reference: PMID:6119011
      reference_title: "Serotonin and dopamine synthesis in phenylketonuria."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."
      explanation: Supports neurotransmitter biosynthesis inhibition; transporter-competition mechanism is an inferred intermediate.
  - target: Reduced Dopamine Biosynthesis
    description: Lower brain tyrosine availability contributes to impaired dopamine synthesis.
    evidence:
    - reference: PMID:6119011
      reference_title: "Serotonin and dopamine synthesis in phenylketonuria."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."
      explanation: Supports dopamine biosynthesis inhibition; transporter competition is an inferred upstream mechanism.
- name: Reduced Serotonin Biosynthesis
  description: High phenylalanine states inhibit serotonin production pathways.
  biological_processes:
  - preferred_term: serotonin biosynthetic process
    term:
      id: GO:0042428
      label: serotonin metabolic process
    modifier: DECREASED
  evidence:
  - reference: PMID:6119011
    reference_title: "Serotonin and dopamine synthesis in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."
    explanation: Human PKU data support reduced serotonin synthesis under high phenylalanine conditions.
  downstream:
  - target: Neurocognitive Dysfunction
    description: Monoamine deficits contribute to attention, executive, and behavioral impairment.
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylketonuria (PKU; also known as phenylalanine hydroxylase (PAH) deficiency) is an autosomal recessive disorder of phenylalanine metabolism, in which especially high phenylalanine concentrations cause brain dysfunction."
      explanation: Supports brain dysfunction in PKU; specific attribution to serotonin deficit is mechanistically plausible but indirect in this source.
- name: Reduced Dopamine Biosynthesis
  description: High phenylalanine states inhibit dopamine production pathways.
  biological_processes:
  - preferred_term: dopamine biosynthetic process
    term:
      id: GO:0042416
      label: dopamine biosynthetic process
    modifier: DECREASED
  evidence:
  - reference: PMID:6119011
    reference_title: "Serotonin and dopamine synthesis in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."
    explanation: Human PKU data support reduced dopamine synthesis under high phenylalanine conditions.
  downstream:
  - target: Neurocognitive Dysfunction
    description: Dopaminergic dysfunction contributes to executive and cognitive deficits.
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylketonuria (PKU; also known as phenylalanine hydroxylase (PAH) deficiency) is an autosomal recessive disorder of phenylalanine metabolism, in which especially high phenylalanine concentrations cause brain dysfunction."
      explanation: Supports PKU-related brain dysfunction; dopaminergic mediation is mechanistic interpretation.
- name: Brain Phenylalanine Toxicity
  description: Elevated phenylalanine in the CNS drives diffuse brain dysfunction.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  biological_processes:
  - preferred_term: nervous system development
    term:
      id: GO:0007399
      label: nervous system development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU; also known as phenylalanine hydroxylase (PAH) deficiency) is an autosomal recessive disorder of phenylalanine metabolism, in which especially high phenylalanine concentrations cause brain dysfunction."
    explanation: Confirms high phenylalanine concentrations as a direct driver of brain dysfunction.
  downstream:
  - target: White Matter and Subcortical Structural Injury
    description: Brain phenylalanine toxicity contributes to persistent white-matter and subcortical abnormalities.
    evidence:
    - reference: PMID:37265600
      reference_title: "Compromised white matter is related to lower cognitive performance in adults with phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In conclusion, our findings demonstrate that white matter alterations in early-treated phenylketonuria persist into adulthood, are most prominent in the posterior white matter and are likely to be driven by axonal damage."
      explanation: Directly supports structural white-matter injury downstream of PKU brain pathology.
  - target: Neurocognitive Dysfunction
    description: Brain dysfunction manifests clinically as cognitive impairment and executive deficits.
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "If untreated, this brain dysfunction results in severe intellectual disability, epilepsy and behavioural problems."
      explanation: Links brain dysfunction directly to neurologic and cognitive outcomes.
- name: White Matter and Subcortical Structural Injury
  description: Treated adults still exhibit white-matter damage and subcortical volume loss associated with phenylalanine burden.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  locations:
  - preferred_term: white matter
    term:
      id: UBERON:0002316
      label: white matter
  biological_processes:
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
    modifier: ABNORMAL
  evidence:
  - reference: PMID:37265600
    reference_title: "Compromised white matter is related to lower cognitive performance in adults with phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In conclusion, our findings demonstrate that white matter alterations in early-treated phenylketonuria persist into adulthood, are most prominent in the posterior white matter and are likely to be driven by axonal damage."
    explanation: Supports persistent white matter injury in adults with early-treated PKU.
  - reference: PMID:38907189
    reference_title: "Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Moreover, these patients showed reduced global white matter volume as well as reductions in the volume of several subcortical grey matter structures, which might be related to the existence of underlying neurodevelopmental alterations."
    explanation: Independently confirms white matter and subcortical structural abnormalities.
  downstream:
  - target: Neurocognitive Dysfunction
    description: Structural brain injury is associated with lower cognitive performance.
    evidence:
    - reference: PMID:37265600
      reference_title: "Compromised white matter is related to lower cognitive performance in adults with phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Furthermore, diffusion tensor imaging metrics in adults with phenylketonuria were related to performance in attention and executive functions."
      explanation: Connects white matter microstructure abnormalities to neurocognitive deficits.
- name: Neurocognitive Dysfunction
  description: PKU causes global and executive cognitive impairment, especially when metabolic control is poor or untreated.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:38907189
    reference_title: "Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adult patients with early-treated PKU showed significantly lower global intelligence than HC."
    explanation: Demonstrates measurable cognitive impairment in early-treated adult PKU cohorts.
  downstream:
  - target: Intellectual Disability
    description: Severe or untreated neurotoxicity can progress to intellectual disability.
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "If untreated, this brain dysfunction results in severe intellectual disability, epilepsy and behavioural problems."
      explanation: Directly links PKU-related brain dysfunction to intellectual disability.
  - target: Seizures
    description: Severe untreated neurotoxicity can present with epilepsy/seizures.
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "If untreated, this brain dysfunction results in severe intellectual disability, epilepsy and behavioural problems."
      explanation: Supports epilepsy as a downstream neurologic consequence.
- name: Impaired Melanin Biosynthesis
  description: Reduced tyrosine availability limits melanin synthesis in untreated or poorly controlled disease.
  biological_processes:
  - preferred_term: melanin biosynthetic process
    term:
      id: GO:0042438
      label: melanin biosynthetic process
    modifier: DECREASED
  chemical_entities:
  - preferred_term: melanins
    term:
      id: CHEBI:25179
      label: melanins
    modifier: DECREASED
  evidence:
  - reference: PMID:30570999
    reference_title: "Phenylketonuria (PKU)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
    explanation: Fair skin in PKU is consistent with reduced pigmentation downstream of tyrosine deficit.
  downstream:
  - target: Hypopigmentation
    description: Reduced melanin production leads to fair skin and lighter pigmentation phenotypes.
    evidence:
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."
      explanation: Supports hypopigmentation as a downstream manifestation of impaired pigmentation biology.
- name: Phenylketone Accumulation
  description: Alternative phenylalanine metabolism increases phenylketones such as phenylpyruvate.
  chemical_entities:
  - preferred_term: phenylpyruvate
    term:
      id: CHEBI:26008
      label: phenylpyruvate
    modifier: INCREASED
  evidence:
  - reference: PMID:21565303
    reference_title: "Study on urinary metabolic profile of phenylketonuria by micellar electrokinetic capillary chromatography with dual electrochemical detection--potential clinical application in fast diagnosis of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The urinary metabolic marker compounds, namely phenylpyruvic acid (PPA), 2-hydroxyphenylacetic acid (oOPAA), 4-hydroxyphenylacetic acid (pOPAA), phenyllactic acid (PLA) and phenylacetic acid (PAA) of phenylketonuric individuals were detected"
    explanation: Confirms phenylketone metabolite accumulation in PKU urine profiles.
  downstream:
  - target: Musty Odor
    description: Phenylketone byproducts contribute to characteristic musty body odor.
    evidence:
    - reference: PMID:30570999
      reference_title: "Phenylketonuria (PKU)."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
      explanation: Supports musty odor phenotype; attribution to specific phenylketone species is mechanistic interpretation.
diagnosis:
- name: Newborn Screening for Hyperphenylalaninemia
  description: Initial diagnosis is made from heel-prick dried blood spot screening.
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylalanine hydroxylase deficiency can be diagnosed by newborn screening based on detection of the presence of hyperphenylalaninemia using the Guthrie microbial inhibition assay or other assays on a blood spot obtained from a heel prick."
    explanation: Defines newborn blood spot screening as the first-line diagnostic modality.
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early diagnosis is based on newborn screening, and if treatment is started early and continued, intelligence is within normal limits with, on average, some suboptimal neurocognitive function."
    explanation: Independent review confirms newborn screening as the basis for early PKU diagnosis.
- name: Plasma Phenylalanine Monitoring
  description: Serial plasma phenylalanine and tyrosine measurement is required for diagnosis and longitudinal control.
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Regular monitoring of plasma phenylalanine and tyrosine concentrations is necessary."
    explanation: Confirms biochemical monitoring as a core diagnostic and management component.
  - reference: PMID:39630157
    reference_title: "Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We strongly recommend lifelong maintenance of Phe ≤360 μmol/L (using plasma or whole blood) for optimal intellectual outcomes and for reduced teratogenicity, utilizing all available and necessary dietary, pharmaceutical, and patient-educational modalities."
    explanation: ACMG guideline independently supports ongoing blood phenylalanine monitoring targets.
- name: PAH Molecular Genetic Testing
  description: Molecular testing confirms PAH deficiency and helps guide treatment selection.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  evidence:
  - reference: PMID:39630157
    reference_title: "Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "genetic testing for PAH variants is recommended at birth to confirm diagnosis and guide therapy."
    explanation: ACMG guideline endorses early PAH genotyping for confirmation and treatment planning.
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Molecular genetic testing of the phenylalanine hydroxylase gene is available for genetic counseling purposes to determine carrier status of at-risk relatives and for prenatal testing."
    explanation: GeneReviews confirms the role of PAH molecular testing in confirmatory and familial risk assessment.
differential_diagnoses:
- name: Hyperphenylalaninemia due to tetrahydrobiopterin deficiency
  description: BH4 cofactor defects can present as newborn-screen positive hyperphenylalaninemia and mimic PAH deficiency.
  disease_term:
    preferred_term: hyperphenylalaninemia due to tetrahydrobiopterin deficiency
    term:
      id: MONDO:0016543
      label: hyperphenylalaninemia due to tetrahydrobiopterin deficiency
  distinguishing_features:
  - Differential testing is required because BH4 deficiency can present with the same initial hyperphenylalaninemia signal as PKU.
  - Separation from PAH deficiency relies on pterin studies and DHPR enzyme activity testing.
  - Patients may develop neurologic abnormalities despite acceptable blood phenylalanine control.
  evidence:
  - reference: PMID:35952926
    reference_title: "Newborn screening and genetic features of patients with hyperphenylalaninemia in a southern Chinese population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Newborn screening is an effective method for early detection of HPA, but differential diagnosis of BH4D is necessary."
    explanation: Explicitly states that BH4 deficiency must be differentiated from PAH-related hyperphenylalaninemia.
  - reference: PMID:8404969
    reference_title: "Differential diagnosis of hyperphenylalaninaemia by a combined phenylalanine-tetrahydrobiopterin loading test."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe a new fully reliable method for the differential diagnosis of tetrahydrobiopterin-dependent hyperphenylalaninaemia (HPA)."
    explanation: Supports dedicated differential workup for BH4-dependent forms.
- name: Dihydropteridine Reductase Deficiency
  description: A BH4 regeneration disorder causing hyperphenylalaninemia with monoamine neurotransmitter deficiency.
  disease_term:
    preferred_term: dihydropteridine reductase deficiency
    term:
      id: MONDO:0009862
      label: dihydropteridine reductase deficiency
  distinguishing_features:
  - DHPR activity testing on dried blood spots is recommended during differential diagnosis.
  - Distinguishing this disorder from PAH deficiency changes treatment strategy beyond phenylalanine restriction alone.
  evidence:
  - reference: PMID:3930839
    reference_title: "Differential diagnosis of tetrahydrobiopterin deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Measurement of DHPR activity in blood spots on Guthrie cards is recommended."
    explanation: Confirms DHPR enzyme testing as a key discriminator in hyperphenylalaninemia workup.
  - reference: PMID:8404969
    reference_title: "Differential diagnosis of hyperphenylalaninaemia by a combined phenylalanine-tetrahydrobiopterin loading test."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It should be performed together with the measurement of dihydropteridine reductase (DHPR) activity in blood."
    explanation: Reinforces that differential diagnosis requires specific DHPR testing.
- name: BH4-deficient hyperphenylalaninemia A
  description: PTS-related BH4 synthesis deficiency that phenotypically overlaps with PKU on newborn screening.
  disease_term:
    preferred_term: BH4-deficient hyperphenylalaninemia A
    term:
      id: MONDO:0009863
      label: BH4-deficient hyperphenylalaninemia A
  distinguishing_features:
  - Caused by BH4 pathway defects (including PTS variants) rather than PAH enzyme deficiency.
  - Requires BH4-focused biochemical and/or genetic testing to identify correctly.
  evidence:
  - reference: PMID:35952926
    reference_title: "Newborn screening and genetic features of patients with hyperphenylalaninemia in a southern Chinese population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 296 newborns who tested HPA positive, 56 were diagnosed with HPA, including 47 with phenylalanine hydroxylase deficiency and nine with tetrahydrobiopterin deficiency (BH4D)."
    explanation: Demonstrates a real newborn-screen cohort where BH4-deficient cases coexist with PAH deficiency and require distinction.
  - reference: PMID:35952926
    reference_title: "Newborn screening and genetic features of patients with hyperphenylalaninemia in a southern Chinese population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-three PAH variants and five PTS variants were detected in HPA patients;"
    explanation: Supports genetic differentiation between PAH-related PKU and PTS-related BH4 deficiency.
- name: Mild Hyperphenylalaninemia
  description: A milder PAH-spectrum condition with lower untreated phenylalanine burden and lower neurologic risk than classic PKU.
  disease_term:
    preferred_term: mild hyperphenylalaninemia
    term:
      id: MONDO:0019335
      label: mild hyperphenylalaninemia
  distinguishing_features:
  - Lower baseline phenylalanine elevations and substantially reduced risk of severe cognitive impairment compared with classic PKU.
  - Phenylalanine thresholds for lifelong intensive treatment differ from classic PKU-range disease.
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mild phenylketonuria and mild hyperphenylalaninemia are associated with lower risk of impaired cognitive development in the absence of treatment."
    explanation: Supports lower neurodevelopmental risk profile relative to classic untreated PKU.
  - reference: PMID:39630157
    reference_title: "Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "treatment for PAH deficiency should be lifelong for individuals with untreated phenylalanine (Phe) levels >360 μmol/L"
    explanation: Guideline threshold helps distinguish lower-range hyperphenylalaninemia from classic PKU requiring strict lifelong treatment targets.
phenotypes:
- name: Intellectual Disability
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Develops if untreated, preventable with early dietary treatment
  phenotype_term:
    preferred_term: Intellectual Disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "If untreated, this brain dysfunction results in severe intellectual disability, epilepsy and behavioural problems."
    explanation: The Nature Reviews Primer confirms severe intellectual disability as a key untreated phenotype.
  - reference: PMID:38907189
    reference_title: "Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Adult patients with PKU showed significantly lower performance than HC in Full Scale IQ"
    explanation: Even early-treated adults show lower IQ compared to healthy controls.
- name: Seizures
  category: Neurological
  frequency: FREQUENT
  notes: Common in untreated patients
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:29025426
    reference_title: "The complete European guidelines on phenylketonuria: diagnosis and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "If left untreated, PKU results in increased phenylalanine concentrations in blood and brain, which cause severe intellectual disability, epilepsy and behavioural problems."
    explanation: European guidelines confirm epilepsy as a major untreated manifestation.
- name: Microcephaly
  category: Neurological
  frequency: FREQUENT
  notes: Result of impaired brain development
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:17092471
    reference_title: "Phenylketonuria in pediatric neurology practice: a series of 146 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition to well-known findings such as mental retardation, autistic features, microcephaly, and tremor, motor retardation was common and responded promptly to dietary treatment."
    explanation: Pediatric PKU case series documents microcephaly among established neurologic manifestations.
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."
    explanation: Review abstract independently supports acquired microcephaly in untreated PKU.
- name: Hypertonia
  category: Neurological
  frequency: OCCASIONAL
  notes: Reported in untreated/poorly controlled disease; less frequent than hypotonia in pediatric series.
  phenotype_term:
    preferred_term: Hypertonia
    term:
      id: HP:0001276
      label: Hypertonia
  evidence:
  - reference: PMID:17092471
    reference_title: "Phenylketonuria in pediatric neurology practice: a series of 146 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hypotonia and diminished reflexes were more frequent findings than hypertonia."
    explanation: Confirms hypertonia occurs in PKU while indicating lower relative frequency.
  - reference: PMID:2516176
    reference_title: "Neurological deterioration in adult phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dietary therapy reduced serum phenylalanine levels, improved symptoms of hypertonicity, and cerebrospinal fluid neurotransmitter metabolites became normal."
    explanation: Adult PKU report supports clinically significant hypertonicity as a neurologic manifestation.
- name: Hypopigmentation
  category: Dermatological
  frequency: VERY_FREQUENT
  notes: Fair skin, light hair, blue eyes due to melanin deficiency
  phenotype_term:
    preferred_term: Hypopigmentation
    term:
      id: HP:0001010
      label: Hypopigmentation of the skin
  evidence:
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."
    explanation: Supports generalized skin, hair, and eye hypopigmentation as a PKU phenotype.
  - reference: PMID:30570999
    reference_title: "Phenylketonuria (PKU)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
    explanation: Fair skin in PKU is consistent with clinical hypopigmentation.
- name: Eczema
  category: Dermatological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Eczema
    term:
      id: HP:0000964
      label: Eczematoid dermatitis
  evidence:
  - reference: PMID:30570999
    reference_title: "Phenylketonuria (PKU)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
    explanation: Clinical overview explicitly lists eczema among PKU manifestations.
- name: Musty Odor
  category: Other
  frequency: FREQUENT
  notes: Due to phenylacetic acid in sweat and urine
  phenotype_term:
    preferred_term: Musty Odor
    term:
      id: HP:0410021
      label: Musty odor
  evidence:
  - reference: PMID:30570999
    reference_title: "Phenylketonuria (PKU)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
    explanation: Clinical overview directly supports musty body odor as a characteristic PKU sign.
biochemical:
- name: Blood Phenylalanine
  presence: Elevated
  context: Greater than 120 micromol/L, often greater than 1200 micromol/L in classic PKU
  evidence:
  - reference: PMID:24385074
    reference_title: "Phenylalanine hydroxylase deficiency: diagnosis and management guideline."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metabolism to be identified through population screening."
    explanation: Supports elevated blood phenylalanine as the defining biochemical abnormality.
  - reference: PMID:21216643
    reference_title: "The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
    explanation: Independent human cohort evidence confirms elevated blood phenylalanine in PKU.
- name: Blood Tyrosine
  presence: Decreased
  context: Low due to blocked conversion from phenylalanine
  evidence:
  - reference: PMID:30570999
    reference_title: "Phenylketonuria (PKU)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Elevated blood Phe levels and decreased Tyr levels characterize PKU."
    explanation: Directly supports low tyrosine as a characteristic biochemical feature.
  - reference: PMID:21216643
    reference_title: "The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
    explanation: Independent cohort data explicitly reports reduced tyrosine in PKU.
- name: Phenylalanine to Tyrosine Ratio
  presence: Elevated
  context: Diagnostic marker
  evidence:
  - reference: PMID:35952926
    reference_title: "Newborn screening and genetic features of patients with hyperphenylalaninemia in a southern Chinese population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients had elevated Phe and Phe/Tyr levels."
    explanation: Supports elevation of the phenylalanine:tyrosine index in diagnosed HPA/PKU cohorts.
  - reference: PMID:21216643
    reference_title: "The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
    explanation: Independent clinical data supports elevated Phe/Tyr ratio as a core PKU biochemical marker.
- name: Phenylpyruvic Acid
  presence: Elevated
  context: Alternative metabolite in urine
  evidence:
  - reference: PMID:21565303
    reference_title: "Study on urinary metabolic profile of phenylketonuria by micellar electrokinetic capillary chromatography with dual electrochemical detection--potential clinical application in fast diagnosis of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The urinary metabolic marker compounds, namely phenylpyruvic acid (PPA), 2-hydroxyphenylacetic acid (oOPAA), 4-hydroxyphenylacetic acid (pOPAA), phenyllactic acid (PLA) and phenylacetic acid (PAA) of phenylketonuric individuals were detected"
    explanation: Supports urinary phenylpyruvic acid elevation as part of the PKU metabolite profile.
genetic:
- name: PAH
  gene_term:
    preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
  association: Causative
  notes: Autosomal recessive; multiple pathogenic PAH variants are reported across populations.
  evidence:
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PKU, an autosomal recessive disease, is an inborn error of phenylalanine (Phe) metabolism caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene."
    explanation: Directly supports PAH as the causative gene in classical PKU.
  - reference: PMID:35952926
    reference_title: "Newborn screening and genetic features of patients with hyperphenylalaninemia in a southern Chinese population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-three PAH variants and five PTS variants were detected in HPA patients; 80.6 % PAH variants and 100 % PTS variants were classified as pathogenic or likely pathogenic."
    explanation: Provides cohort-level evidence for multiple pathogenic PAH variants in HPA/PKU.
environmental:
- name: Dietary Phenylalanine
  notes: Primary determinant of metabolic control
  evidence:
  - reference: PMID:24385074
    reference_title: "Phenylalanine hydroxylase deficiency: diagnosis and management guideline."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment has predominantly been dietary manipulation, and use of low protein and phenylalanine medical foods is likely to remain a major component of therapy for the immediate future."
    explanation: Supports that phenylalanine intake control through diet is central to metabolic management.
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dietary treatment, including natural protein restriction and Phe-free supplements, must be used to maintain blood Phe concentrations of 120-360 μmol/L throughout the life span."
    explanation: Independent review supports dietary phenylalanine restriction as a central environmental determinant of metabolic control.
- name: Mammalian Meat Intake
  notes: Representative high-protein phenylalanine-rich food source requiring restriction
  food_source:
    preferred_term: mammalian meat food product
    term:
      id: FOODON:00001006
      label: mammalian meat food product
- name: Dairy Intake
  notes: Milk and related dairy foods contribute to dietary phenylalanine burden
  food_source:
    preferred_term: milk
    term:
      id: FOODON:03302116
      label: cow milk (liquid)
- name: Nut Intake
  notes: Nuts are concentrated protein sources that contribute to dietary phenylalanine burden
  food_source:
    preferred_term: nut
    term:
      id: FOODON:03303171
      label: nut
- name: Aspartame
  notes: Contains phenylalanine, must be avoided
  evidence:
  - reference: PMID:33672234
    reference_title: "Accidental Consumption of Aspartame in Phenylketonuria: Patient Experiences."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Aspartame is a phenylalanine containing sweetener, added to foods and drinks, which is avoided in phenylketonuria (PKU)."
    explanation: Directly supports aspartame avoidance as a relevant environmental exposure issue in PKU.
  - reference: PMID:3291200
    reference_title: "Aspartame: review of recent experimental and observational data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Persons suffering from phenylketonuria (PKU-homozygotes) on a phenylalanine-restricted diet should avoid consumption of aspartame."
    explanation: Independent review supports specific aspartame avoidance guidance in PKU.
treatments:
- name: Phenylalanine-Restricted Diet
  description: Lifelong dietary restriction of phenylalanine intake, mainstay of treatment.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
    dietary_modifications:
    - action: RESTRICT
      food:
        preferred_term: mammalian meat food product
        term:
          id: FOODON:00001006
          label: mammalian meat food product
    - action: RESTRICT
      food:
        preferred_term: milk
        term:
          id: FOODON:03302116
          label: cow milk (liquid)
    - action: RESTRICT
      food:
        preferred_term: nut
        term:
          id: FOODON:03303171
          label: nut
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dietary restriction of phenylalanine has been the mainstay of treatment for over 60 years and has been highly successful, although outcomes are still suboptimal and patients can find the treatment difficult to adhere to."
    explanation: Confirms diet as the primary and long-standing treatment approach.
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mainstay of treatment for hyperphenylalaninemia involves a low-protein diet and use of a phenylalanine-free medical formula."
    explanation: Independent clinical review confirms low-protein dietary treatment as standard of care.
- name: Medical Formula
  description: Phenylalanine-free amino acid supplements to provide protein needs.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mainstay of treatment for hyperphenylalaninemia involves a low-protein diet and use of a phenylalanine-free medical formula."
    explanation: Directly supports phenylalanine-free medical formula as standard PKU therapy.
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dietary treatment, including natural protein restriction and Phe-free supplements, must be used to maintain blood Phe concentrations of 120-360 μmol/L throughout the life span."
    explanation: Independent review confirms ongoing use of Phe-free supplementation in PKU management.
- name: Sapropterin (Kuvan)
  description: BH4 cofactor replacement for responsive patients, allows dietary liberalization.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: sapropterin
      term:
        id: CHEBI:59560
        label: sapropterin
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"
    explanation: Confirms sapropterin (BH4) effectiveness in a subset of patients with milder disease.
  - reference: PMID:17693179
    reference_title: "Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In some patients with phenylketonuria who are responsive to BH4, sapropterin treatment to reduce blood phenylalanine could be used as an adjunct to a restrictive low-phenylalanine diet, and might even replace the diet in some instances."
    explanation: Phase III trial evidence supports sapropterin efficacy in BH4-responsive PKU.
- name: Pegvaliase (Palynziq)
  description: Enzyme substitution therapy using PEGylated phenylalanine ammonia lyase.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: pegvaliase
      term:
        id: NCIT:C174744
        label: Pegvaliase
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "pegylated phenylalanine ammonia lyase, which requires daily subcutaneous injections and causes adverse immune responses"
    explanation: Confirms pegvaliase as an available treatment, noting its route and immunogenicity concerns.
  - reference: PMID:29628378
    reference_title: "Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Results from this study confirmed the efficacy of pegvaliase in maintaining reduced blood Phe concentrations with a manageable safety profile for most participants."
    explanation: Pivotal Phase 3 trial independently supports pegvaliase efficacy and tolerability profile.
- name: Large Neutral Amino Acids
  description: Compete with phenylalanine for brain transport, adjunctive therapy.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:987768
    reference_title: "Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Increasing the serum concentrations of amino acids competitive with phenylalanine for transport across the blood brain barrier might form an alternative approach to effective dietary treatment of PKU."
    explanation: Supports LNAA supplementation rationale as an adjunctive PKU dietary strategy.
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional treatments include the casein glycomacropeptide (GMP), which contains very limited aromatic amino acids and may improve immunological function, and large neutral amino acid (LNAA) supplementation to prevent plasma Phe transport into the brain."
    explanation: Human PKU review independently supports LNAA supplementation as an adjunctive treatment strategy.
datasets:
- accession: geo:GSE294755
  title: "Whole transcriptome comparison between two groups of PKU patients: Non-carriers vs. Carriers of rs113883650"
  description: Transcriptomic profiling dataset comparing PKU carrier/non-carrier groups under differing phenylalanine exposure conditions.
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_types:
  - preferred_term: patient-derived cells
    term:
      id: CL:0000000
      label: cell
  sample_count: 19
  conditions:
  - PKU non-carrier group
  - PKU carrier group (rs113883650)
  - high phenylalanine condition
  - low phenylalanine condition
  publication: PMID:41387948
  evidence:
  - reference: geo:GSE294755
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We demonstrated a decrease of expression of proteasome pathway (KEGG) incells treated with high Phe concentrations."
    explanation: Dataset-level summary supports relevance to PKU high-phenylalanine cellular response.
  findings:
  - statement: High-phenylalanine conditions in this cohort were associated with reduced expression of proteasome pathway genes.
    evidence:
    - reference: geo:GSE294755
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We demonstrated a decrease of expression of proteasome pathway (KEGG) incells treated with high Phe concentrations."
      explanation: GEO summary reports pathway-level transcriptomic changes under high phenylalanine exposure.
- accession: geo:GSE112108
  title: Does early treatment of PKU patients with sapropterin dihydrochloride affect brain development?
  description: RNA-seq from organotypic rat brain cultures exposed to sepiapterin/BH4 to model developmental effects relevant to early PKU treatment contexts.
  organism:
    preferred_term: Rattus norvegicus
    term:
      id: NCBITaxon:10116
      label: Rattus norvegicus
  data_type: BULK_RNA_SEQ
  sample_types:
  - preferred_term: organotypic brain cell culture
    term:
      id: CL:0000000
      label: cell
    tissue_term:
      preferred_term: brain
      term:
        id: UBERON:0000955
        label: brain
  sample_count: 23
  conditions:
  - sepiapterin-treated
  - untreated control
  - early developmental stage
  - later developmental stage
  evidence:
  - reference: geo:GSE112108
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "RNAseq analyses revealed a number of significantly affected genes."
    explanation: Supports utility of this dataset for transcriptomic analysis of early PKU-treatment-relevant brain effects.
  findings:
  - statement: Early-stage sepiapterin exposure showed transcriptomic and cellular evidence of disturbed neural development, with increased apoptosis and altered glial/axonal markers.
    evidence:
    - reference: geo:GSE112108
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "RNAseq analyses revealed a number of significantly affected genes."
      explanation: Dataset summary confirms measurable transcriptional perturbations in treated developing brain cultures.
    - reference: geo:GSE112108
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Immunofluorescence for activated caspase-3 revealed an increased apoptosis rate."
      explanation: Summary links treatment exposure to increased apoptosis in the early developmental stage.
- accession: geo:GSE55148
  title: Mildly compromised tetrahydrobiopterin biosynthesis mouse mutants exhibit abnormal body fat distribution and abdominal obesity
  description: Mouse expression profiling study of reduced BH4 biosynthesis (Pts mutant models), relevant to BH4-deficient hyperphenylalaninemia mechanisms.
  organism:
    preferred_term: Mus musculus
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: MICROARRAY
  sample_types:
  - preferred_term: brain tissue
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: liver tissue
    term:
      id: UBERON:0002107
      label: liver
  sample_count: 16
  conditions:
  - Pts mutant mice
  - wild-type controls
  evidence:
  - reference: geo:GSE55148
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "BH4 deficiency due to an autosomal recessive defect in its biosynthetic enzyme 6-pyruvoyltetrahydropterin synthase (PTPS, encoded by the PTS gene) leads to a variant form of hyperphenylalaninemia concomitant with severe deficiency of brain monoamine neurotransmitters."
    explanation: Dataset-level summary supports relevance to BH4-associated hyperphenylalaninemia mechanisms.
  findings:
  - statement: BH4-biosynthesis impairment in this model produced metabolic phenotypes relevant to BH4-associated hyperphenylalaninemia.
    evidence:
    - reference: geo:GSE55148
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "BH4 deficiency due to an autosomal recessive defect in its biosynthetic enzyme 6-pyruvoyltetrahydropterin synthase (PTPS, encoded by the PTS gene) leads to a variant form of hyperphenylalaninemia concomitant with severe deficiency of brain monoamine neurotransmitters."
      explanation: Summary supports translational relevance of BH4-pathway models to differential hyperphenylalaninemia biology.
clinical_trials:
- name: NCT00838435
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Phase 3b open-label Kuvan study in young children with PKU evaluating safety,
    neurocognitive outcomes, blood phenylalanine maintenance, and growth.
  target_phenotypes:
  - preferred_term: Intellectual Disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: clinicaltrials:NCT00838435
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This multicenter, open label study is designed to evaluate the safety of Kuvan® and its effect on neurocognitive function, blood Phe concentration, and growth in children with PKU who are 0-6 years old."
    explanation: Trial synopsis confirms explicit clinical endpoints relevant to PKU neurocognitive disease burden.
- name: NCT01212744
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Phase 2 open-label trial of daily subcutaneous rAvPAL-PEG evaluating safety,
    tolerability, and efficacy for blood phenylalanine reduction in PKU.
  target_phenotypes:
  - preferred_term: Intellectual Disability
    term:
      id: HP:0001249
      label: Intellectual disability
  - preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: clinicaltrials:NCT01212744
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to evaluate the effect of daily administration of rAvPAL-PEG on the reduction of blood Phe concentrations in subjects with PKU."
    explanation: Confirms interventional targeting of the core biochemical driver in PKU.
- name: NCT04534842
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Open-label Phase 2 SynPheny-1 trial assessing efficacy and safety of
    SYNB1618/SYNB1934 oral biotherapeutic regimens in PKU.
  target_phenotypes:
  - preferred_term: Intellectual Disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: clinicaltrials:NCT04534842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This Phase 2 study in patients with phenylketonuria (PKU) will be an open-label, dual-arm study of either a SYNB1618 or SYNB1934 dose-ramp regimen."
    explanation: Confirms active interventional evaluation of novel PKU therapeutics in a defined patient cohort.
computational_models:
- name: Multi-compartment PKU FBA Model
  description: Three-compartment FBA model with explicit blood-brain barrier transport for aromatic amino acids
  model_type: FLUX_BALANCE_ANALYSIS
  base_model: Recon-derived
  perturbations:
  - preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
    modifier: ABSENT
  publication: PMID:36880400
  evidence:
  - reference: PMID:36880400
    reference_title: "Competitive, multi-objective, and compartmented Flux Balance Analysis for addressing tissue-specific inborn errors of metabolism."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "We built a three-compartment model, made the common transport across the BBB explicit, and included dopamine and serotonin synthesis as parts of the brain function to be delivered by FBA."
    explanation: Directly supports model architecture and PKU-relevant mechanistic scope.
  notes: Explains brain-specific pathology and why Phe restriction outperforms Tyr supplementation
- name: Recon3D with PAH knockout
  description: Human genome-scale metabolic model simulating phenylalanine hydroxylase deficiency
  model_type: GENOME_SCALE_METABOLIC
  base_model: Recon3D
  repository_url: https://github.com/VirtualMetabolicHuman/Recon
  model_id: Recon3D
  model_software: COBRApy
  model_format: SBML
  perturbations:
  - preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
    modifier: ABSENT
  publication: PMID:29457794
  evidence:
  - reference: PMID:29457794
    reference_title: "Recon3D enables a three-dimensional view of gene variation in human metabolism."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Recon3D represents the most comprehensive human metabolic network model to date, accounting for 3,288 open reading frames (representing 17% of functionally annotated human genes), 13,543 metabolic reactions involving 4,140 unique metabolites, and 12,890 protein structures."
    explanation: Supports use of Recon3D as a genome-scale computational base model for metabolic disease simulation.
- name: Harvey Whole-Body PKU Model
  description: Sex-specific whole-body model for organ-resolved IEM biomarker prediction.
  model_type: GENOME_SCALE_METABOLIC
  base_model: Harvey 1.0
  repository_url: https://www.vmh.life/
  perturbations:
  - preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
    modifier: ABSENT
  publication: PMID:32463598
  evidence:
  - reference: PMID:32463598
    reference_title: "Personalized whole-body models integrate metabolism, physiology, and the gut microbiome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "We developed a new metabolic network reconstruction approach that used organ-specific information from literature and omics data to generate two sex-specific whole-body metabolic (WBM) reconstructions."
    explanation: Supports whole-body sex-specific metabolic reconstruction framework underlying Harvey/Harvetta-style models.
  - reference: PMID:32463598
    reference_title: "Personalized whole-body models integrate metabolism, physiology, and the gut microbiome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "We also illustrate that the WBM models can predict known biomarkers of inherited metabolic diseases in different biofluids."
    explanation: Supports biomarker prediction capability relevant to PKU and related IEM applications.
  notes: Whole-body WBM framework supports organ-resolved biomarker prediction in inherited metabolic disease.
- name: Full-Length PAH Tetramer Crystal Structure
  description: >-
    Crystal structure of full-length human phenylalanine hydroxylase (hPAH) tetramer
    at 3.06 angstrom resolution in the resting-state conformation, combined with
    SEC-SAXS analysis of both resting and Phe-activated states. Reveals that allosteric
    Phe binding favors an activated tetramer conformation biophysically distinct in
    solution, with the Phe-binding regulatory module positioned 8-10 angstrom farther
    from the tetramer center than previously modeled.
  model_type: STRUCTURAL_PREDICTION
  publication: PMID:31076506
  findings:
  - statement: First crystal structure of full-length PAH tetramer reveals resting-state architecture
  - statement: Allosteric Phe binding induces a distinct activated conformation detectable by SAXS
  evidence:
  - reference: PMID:31076506
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "a tractable C29S variant of hPAH (C29S) yielded a 3.06 Å resolution crystal structure of the tetrameric resting-state conformation."
    explanation: First crystal structure of full-length PAH provides structural basis for understanding PKU-causing mutations.
  - reference: PMID:31076506
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "The structural insights into allosteric activation of hPAH reported here may help inform ongoing efforts to treat phenylketonuria with novel therapeutic approaches."
    explanation: Structural insights directly relevant to PKU therapeutic development.
- name: PAH Regulatory Domain Phe-Binding Crystal Structure
  description: >-
    Crystal structure of the human PAH N-terminal regulatory domain (PAH-RD) bound
    with Phe at 1.8 angstrom resolution, revealing a homodimer of ACT folds with Phe
    bound at the dimer interface. Demonstrates that Phe binding mediates dimerization
    of regulatory modules, providing structural evidence for the allosteric activation
    mechanism and explaining how disease-associated mutations that impair Phe binding
    disrupt the monomer:dimer equilibrium.
  model_type: STRUCTURAL_PREDICTION
  publication: PMID:27049649
  findings:
  - statement: Phe binds at the dimer interface of PAH regulatory domain ACT folds
  - statement: Disease-associated PAH mutations impair Phe binding and disrupt regulatory domain dimerization
  evidence:
  - reference: PMID:27049649
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "a disease-associated PAH mutant impaired in Phe binding disrupts the monomer:dimer equilibrium of PAH-RD."
    explanation: Crystal structure explains how PKU-causing mutations disrupt allosteric regulation of PAH activity.
classifications:
  harrisons_chapter:
  - classification_value: hereditary disease
    evidence:
    - reference: PMID:21555948
      reference_title: "Phenylalanine hydroxylase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylalanine hydroxylase deficiency is an autosomal recessive disorder that results in intolerance to the dietary intake of the essential amino acid phenylalanine."
      explanation: Supports classification of PKU as a hereditary disease.